ScholarIQanswers from OpenAlex & ORCID
Jeffrey C. Allen
ResearcherPublications, citations & collaboration network
Jeffrey C. Allen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jeffrey C. Allen have?
ScholarIQindexed works
Jeffrey C. Allen has 715 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jeffrey C. Allen have?
ScholarIQcitation count
Jeffrey C. Allen has 31,916 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jeffrey C. Allen?
ScholarIQh-index
Jeffrey C. Allen has an h-index of 89 in OpenAlex.
What is the i10-index of Jeffrey C. Allen?
ScholarIQi10-index
Jeffrey C. Allen has an i10-index of 356 in OpenAlex.
What is the ORCID of Jeffrey C. Allen?
ScholarIQorcid
The ORCID for Jeffrey C. Allen is on the source record.
What is the OpenAlex record for Jeffrey C. Allen?
ScholarIQopenalex
The OpenAlex for Jeffrey C. Allen is on the source record.
What are the most-cited papers on Jeffrey C. Allen?
ScholarIQmost cited works
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
Cathy Bennett, Nimish Vakil, Jacques Bergman, Rebecca Harrison, Robert D. Odze, Michael Vieth, S. Sanders, Laura Gay, Oliver Pech, Gaius Longcroft‐Wheaton, Yvonne Romero, John M. Inadomi, Jan Tack, Douglas A. Corley, Hendrik Manner, Susi Green, David Al Dulaimi, Haythem Ali, Bill Allum, Mark Anderson, Howard J. Curtis, Gary W. Falk, M. Brian Fennerty, Grant Fullarton, Kausilia K. Krishnadath, Stephen J. Meltzer, David Armstrong, Robert A. Ganz, Gianpaolo Cengia, James J. Going, John R. Goldblum, Charles A. Gordon, Heike I. Grabsch, Chris Haigh, Michio Hongo, David Johnston, Ricky Forbes–Young, Elaine W. Kay, Philip Kaye, Toni Lerut, Laurence Lovat, Lars Lundell, Philip Mairs, Tadakuza Shimoda, Stuart J. Spechler, Stephen J. Sontag, Peter Malfertheiner, Iain Murray, Manoj Nanji, David Poller, Krish Ragunath, Jarosław Reguła, Renzo Cestari, Neil A. Shepherd, Rajvinder Singh, H. J. Stein, Nicholas J. Talley, Jean–Paul Galmiche, Tony Tham, Peter Watson, Lisa Yerian, Massimo Rugge, Thomas W. Rice, John Hart, Stuart Gittens, David Hewin, J Hochberger, Peter Kahrilas, Sean Preston, Richard E. Sampliner, Prateek Sharma, Robert K. Stuart, Kenneth T. Wang, Irving Waxman, Chris Abley, Duncan E. Loft, Ian Penman, Nicholas J. Shaheen, Amitabh Chak, Gareth Davies, Lorna Dunn, Yngve Falck–Ytter, John de Caestecker, Pradeep Bhandari, Christian Ell, S M Griffin, Stephen Attwood, Hugh Barr, Jeffrey C. Allen, Mark K. Ferguson, Paul Moayyedi, Janusz Jankowski
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian Weiss, Pamela L. Wolters, Scott R. Plotkin, Brigitte C. Widemann, James H. Tonsgard, Jaishri O. Blakeley, Jeffrey C. Allen, Elizabeth K. Schorry, Bruce R. Korf, Nathan Robison, Stewart Goldman, Alexander A. Vinks, Chie Emoto, Tsuyoshi Fukuda, Coretta Thomas Robinson, Gary Cutter, Lloyd J. Edwards, Eva Dombi, Nancy Ratner, Roger J. Packer, Michael J. Fisher